TY - JOUR
T1 - Effect of orlistat on serum uric acid level in adults
T2 - A systematic review and meta-analysis of randomised controlled trials
AU - Noori, Soheila
AU - Mirzababaei, Atieh
AU - Amini, Mohammad Reza
AU - Clark, Cain C.T.
AU - Mirzaei, Khadijeh
N1 - Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PY - 2021/11
Y1 - 2021/11
N2 - Objective: Hyperuricemia increases the risk of gout and cardiovascular diseases. Obesity increases the risk of hyperuricemia while weight loss (>5 kg) has been reported to decrease urate. The effects of orlistat on serum uric acid (SUA) are still controversial. The aim of this meta-analysis was to evaluate the influence of orlistat on SUA levels in adults. Methods: Relevant studies, published up to May 2020, were searched systematically through PubMed/Medline, Scopus and Google Scholar. All relevant randomised controlled clinical trials were included. Meta-analysis was performed using random-effect model. Subgroup analysis, sensitivity analysis and meta-regression were also carried out. Results: Overall 7 trials (9 datasets) that enrolled 1786 subjects were included. Orlistat showed in a significant change in SUA level (Difference in means: −17.661 μmol, 95% CI: −31.615 to −3.707, P =.01). A low heterogeneity observed across the studies (I2 = 25.119%). After categorising studies on the basis of duration and sample size, the effect of orlistat on SUA was significant. The results of meta-regression were showed that significant relationships were not found between orlistat and SUA in the duration of intervention. Conclusion: We found a significant reduction in SUA following orlistat therapy in adults.
AB - Objective: Hyperuricemia increases the risk of gout and cardiovascular diseases. Obesity increases the risk of hyperuricemia while weight loss (>5 kg) has been reported to decrease urate. The effects of orlistat on serum uric acid (SUA) are still controversial. The aim of this meta-analysis was to evaluate the influence of orlistat on SUA levels in adults. Methods: Relevant studies, published up to May 2020, were searched systematically through PubMed/Medline, Scopus and Google Scholar. All relevant randomised controlled clinical trials were included. Meta-analysis was performed using random-effect model. Subgroup analysis, sensitivity analysis and meta-regression were also carried out. Results: Overall 7 trials (9 datasets) that enrolled 1786 subjects were included. Orlistat showed in a significant change in SUA level (Difference in means: −17.661 μmol, 95% CI: −31.615 to −3.707, P =.01). A low heterogeneity observed across the studies (I2 = 25.119%). After categorising studies on the basis of duration and sample size, the effect of orlistat on SUA was significant. The results of meta-regression were showed that significant relationships were not found between orlistat and SUA in the duration of intervention. Conclusion: We found a significant reduction in SUA following orlistat therapy in adults.
KW - General Medicine
UR - http://www.scopus.com/inward/record.url?scp=85113326222&partnerID=8YFLogxK
U2 - 10.1111/ijcp.14674
DO - 10.1111/ijcp.14674
M3 - Article
C2 - 34324762
AN - SCOPUS:85113326222
SN - 1368-5031
VL - 75
JO - International Journal of Clinical Practice
JF - International Journal of Clinical Practice
IS - 11
M1 - e14674
ER -
